Deal Ticker: Kellerhals Carrard advises the shareholders of GENE PREDICTIS SA on its sale to NIMGenetics Genomica y Medicina, S.L.
Kellerhals Carrard advised the shareholders of GENE PREDICTIS SA, a Swiss-based medical diagnostic company and leader in the field of preventive health and precision medicine, in a sale transaction to NIMGenetics Genomica y Medicina, S.L., a leading Spanish biotech company in the field of human genetic diagnostics and a portfolio company of Apposite Capital.
The Kellerhals Carrard team comprised Frédéric Rochat and Anne-Gabrielle Piaget.